MediMabBio

What MediMabBio does

MediMabBio is a clinical-stage biopharmaceutical company founded in 2017 in Seongnam, South Korea, that develops fusion antibody immunotherapies for cancer and autoimmune/inflammatory diseases. The company operates two proprietary technology platforms: MediLink™, a plug-and-play fusion antibody architecture that integrates target-specific antibodies with engineered cytokines to enable programmable biological functions, and MediKine™, an engineered cytokine platform that controls signaling strength, duration and quality to widen the therapeutic window. Its pipeline consists of three programs — MFA011, an aTIGIT-IL15 fusion antibody for oncology; MFA031, a first-in-class TIGIT agonist-IL-10 fusion therapeutic for autoimmune disease; and MFA041, a discovery-stage autoimmune candidate — all currently preclinical and supported by collaborations with the University of Oxford, University of Birmingham, KAIST and Thermo Fisher Scientific as CDMO partner. The company is led by Founder & Co-CEO Jennifer Yuhoi Kang (D.Phil, Oxford; post-doc, Harvard Medical School) and runs a small scientific team in which over 90% hold advanced degrees.

The business model is pre-revenue and partnering-focused: MediMabBio does not sell product but pursues out-licensing, co-development, platform collaborations and strategic research partnerships with global pharmaceutical companies, with deal flow generated through direct BD outreach ([email protected]), major scientific conferences (AACR, Cytokines, EACR) and Korean government programs such as KHIDI's Boston C&D Incubation and Global Marketing Support programs and Celltrion's Open Innovation. Expected revenue streams are upfront payments, milestones and royalties from such licensing deals, though none has been disclosed to date. The company has operations in South Korea (headquarters, Pangyo Technovalley), the United Kingdom (MediMab Biotherapeutics Ltd., Oxford BioEscalator) and the United States (Boston/Cambridge CIC), funded to date by a TIPS grant (up to USD 1M, 2017), pre-Series A (USD 3M, 2019), Series A (USD 18M, 2021) and Series B (KRW 25.6B / ~USD 17M, 2025), and recognized with awards including Innovation Tiger 2025 Grand Prize in Japan and Best Employer honors from the Seongnam City Council.

Name

MediMabBio

Legal name

MediMabBio Inc.

Website

https://medimabbio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MediMabBio is a South Korea-based biotherapeutic company developing fusion antibody immunotherapies for cancer and autoimmune diseases via its proprietary MediLink™ and MediKine™ platforms, pursuing out-licensing partnerships with global pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Antibody immunotherapy
• Oncology biologics
• Autoimmune therapeutics
• Biotech licensing
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Out-licensing and Co-development Deals: Pre-revenue biotech company pursuing partnerships with global pharmaceutical companies for out-licensing of pipeline assets and platform technologies. Revenue expected through upfront payments, milestone payments, and royalties from licensing agreements.
2. Strategic Research Partnerships: Collaborative research partnerships with pharmaceutical companies for co-development of therapeutics, potentially generating research funding, milestone payments, and co-commercialization rights.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MediMabBio develops antibody-based immunotherapies for oncology and autoimmune diseases using two proprietary platforms, MediLink™ and MediKine™. Its pipeline includes MFA011 (oncology), MFA031 (autoimmune), and MFA041 (early discovery), which it advances toward clinical development and out-licenses to global pharmaceutical partners. The company is pre-revenue and monetizes through licensing, partnerships, and milestone payments.

Product overview

MediMabBio is a biopharmaceutical company developing next-generation immunotherapies through its proprietary MediLink™ fusion-antibody platform and MediKine™ engineered cytokine platform. The company's product portfolio consists of three pipeline programs: MFA011 (aTIGIT-IL15 fusion antibody for cancer), MFA031 (TIGIT agonist-IL-10 fusion therapeutic for autoimmune diseases), and MFA041 (in discovery for autoimmune diseases). These fusion antibody therapeutics combine antibodies with immune-modulating cytokines to deliver enhanced therapeutic efficacy and safety compared to conventional approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• MFA011 Antibody-based immunotherapy candidate for oncology indications, developed using MediMabBio's proprietary MediLink™ and/or MediKine™ platforms and intended for out-licensing to global pharmaceutical partners.
• MFA031 Antibody-based immunotherapy candidate targeting autoimmune disease indications, developed using MediMabBio's proprietary antibody engineering platforms and intended for out-licensing to global pharmaceutical partners.
• MFA041 Early discovery-stage antibody immunotherapy candidate from MediMabBio's pipeline.

Quantifiable outcome

• MFA011 demonstrated enhanced anti-tumor efficacy and reduced immunotoxicity in preclinical models compared to conventional TIGIT-targeting agents
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, strategic and minor.

• Korea Health Industry Development Institute (KHIDI)coreGTM or Marketing Partner · 22 May 2026Boston Connect & Development Incubation Office program. Establishes presence at Cambridge Innovation Center (CIC) in Boston's Kendall Square to strengthen clinical development capabilities in US and expand global partnership opportunities.
• Korea Health Industry Development Institute (KHIDI)coreGTM or Marketing Partner · 1 May 2026Global Marketing Support Program for Pharmaceutical and Biotechnology Companies under K-VIP (Korea BioHealth Value-up Innovation Program). Supports expansion of global presence through international marketing activities, global networks, and strategic business partners.
• PDC*line PharmastrategicStrategic or Co-development Partner · 30 April 2024MoU collaboration to explore synergy between MediMabBio's MMB101/MFA011 and PDC*line Pharma's plasmacytoid dendritic cell (PDC) cancer vaccines. Aims to enhance efficacy of cancer treatments targeting TIGIT and other immuno-oncology pathways.
• CelltrionstrategicStrategic or Co-development Partner · 30 January 2024Selected as one of four biotech startups for Celltrion's Open Innovation Program, in partnership with Seoul Biohub. Part of Celltrion's strategy to drive biotech innovation. MediMabBio benefits from Celltrion's extensive network, resources, and expertise.
• University of OxfordcoreStrategic or Co-development Partner · 27 May 2020Research collaboration and pipeline development partnership. UK subsidiary established within Oxford's BioEscalator to strengthen R&D collaborations. Focus on broadening pipeline development and technology transfers.
• University of Birmingham / University Hospitals BirminghamcoreStrategic or Co-development PartnerComprehensive research collaboration on liver cancer treatment, autoimmune diseases, and NASH treatment. Partnership intensifies preparations for global clinical stage entry of main pipelines.
• KAISTcoreStrategic or Co-development PartnerResearch collaboration for pipeline development leveraging Korean academic expertise in biological sciences.
• Thermo Fisher ScientificcoreImplementation/ SI/ Consulting PartnerCDMO partnership for Contract Development and Manufacturing Organization services. Utilizes Thermo Fisher's Quick to Clinic (QTC) solution to optimize development timelines and costs for lead asset MMB101 (now MFA011).
• AstraZenecastrategicStrategic or Co-development PartnerThrough KHIDI's Project NOVA at BIO International Convention in San Diego, MediMabBio participated in partnering sessions with AstraZeneca experts. 13 Korean biotech firms specializing in immunology, oncology, and nephrology/metabolic diseases presented technologies for evaluation as part of Korea's open innovation strategy.
• 아산재단 (Asan Foundation)minorStrategic or Co-development PartnerResearch collaboration partnership for pipeline development.
• Bio EscalatorminorStrategic or Co-development PartnerUK subsidiary housed at Bio Escalator for access to UK biotech ecosystem and incubation support.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• MacroGenics: US clinical-stage biotech with multiple bispecific antibody programs in oncology (enoblituzumab, MGD019) and autoimmune indications. Larger incumbent in the bispecific oncology space; useful comp for platform deal economics.

Direct peers

• Werewolf Therapeutics: US clinical-stage biotech engineering INDUKINE™ masked cytokines for tumor-selective activation. Closest mechanistic peer to MediKine™ given shared approach of engineering cytokines to improve therapeutic window.
• ABL Bio: Korean clinical-stage bispecific antibody biotech developing immuno-oncology and neurodegenerative disease therapeutics. Closest geographic and modality peer — also leverages antibody engineering platforms for next-generation biologics with global pharma partnerships.
• Compugen: Israel-based immuno-oncology biotech focused on TIGIT and PVRIG pathways. Direct TIGIT competitor with COM701 in clinical development; useful reference for TIGIT pathway deal economics.
• iTeos Therapeutics: Clinical-stage immuno-oncology company developing anti-TIGIT (eosine-2/3) antibodies. Direct TIGIT-target competitor with EOS-448 partnered with GSK; relevant benchmark for TIGIT asset value and deal comps.
• Y-Biologics: Korean biotech developing bispecific antibody and adoptive cell therapy platforms. Peer Korean antibody engineering company at similar stage and scale; comparable business model of platform-enabled partnerships.
• Xilio Therapeutics: US clinical-stage biotech developing tumor-activated cytokine immunotherapies. Comparable modality and stage to MediMabBio's cytokine-fusion approach with shared therapeutic-window optimization thesis.

Emerging players

• Innate Pharma: French clinical-stage immuno-oncology company developing NK cell engagers and TIGIT-targeting antibodies. Partial overlap in TIGIT and NK cell biology relevant to MFA011's mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/medimabbio
• LinkedInlinkedin.com/company/medimabbio

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediMabBio